Figure 3
At St Jude Children's Research Hospital, dosages of high-dose methotrexate are individualized based on the estimates of clearance to achieve a desired systemic exposure to the drug. As shown, in a patient estimated to have low clearance (40 mL/min per m2; A), the dosage should be lowered to achieve the desired steady-state plasma concentration to reduce potential toxicities (B). Those patients with high clearance have dosages increased.
